Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (NYSE: LLY) is getting mixed attention, with the shares under pressure from headlines that employers may scale back coverage for GLP-1 weight-loss drugs, while several other updates continue to support the long-term growth story.

• Positive Sentiment: Goldman Sachs reiterated a buy rating on Eli Lilly, pointing to its encouraging obesity-treatment pipeline and continued investor enthusiasm around the company’s growth prospects. Goldman Sachs Maintains a Buy Rating on Eli Lilly (LLY), Cites Encouraging Obesity Treatment Pipeline
• Positive Sentiment: Analysts at Erste Group raised FY2026 and FY2027 EPS estimates for Eli Lilly, which signals expectations for stronger earnings momentum ahead.
• Positive Sentiment: Eli Lilly’s investment in Abridge links it to healthcare AI, with the goal of improving drug development, trial enrollment and research productivity. Eli Lilly’s Abridge Bet Links Healthcare AI To Valuation And Growth
• Positive Sentiment: New clinical and pipeline updates, including a Phase 2 osteoarthritis trial and a chronic low-back-pain study, suggest Eli Lilly is broadening beyond obesity and diabetes into additional therapeutic areas. Eli Lilly Expands Chronic Pain Pipeline With New Osteoarthritis Trial
• Neutral Sentiment: Coverage highlighting Eli Lilly as a growth stock, trading in a buy zone, and drawing institutional buying reinforces positive sentiment, but does not add new company-specific news. Eli Lilly Stock Hits Buy Zone As Earnings Soar 156%. Funds Are Loading Up.
• Negative Sentiment: Reuters reported that some U.S. employers may drop coverage for GLP-1 obesity drugs in 2027, which could slow future uptake of Eli Lilly’s Zepbound and Foundayo if benefit coverage becomes harder to secure. Some US employers to drop coverage of GLP-1 obesity drugs in 2027 as use increases

Overall, LLY is being supported by strong earnings expectations, pipeline progress, and strategic investments, but the stock is also facing a valuation/coverage risk tied to whether employers continue paying for expensive GLP-1 therapies.